Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.41 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246768 | 1.00 | DPP4 (0.42) | DPP4DPP7DPP8DPP9ACE | |
| SCHEMBL3796746 | 0.92 | DPP4 (0.49) | DPP4DPP7DPP8DPP9ACE | |
| SCHEMBL10782979 | 0.85 | ACE (0.53) | ACEOPRK1 | |
| SCHEMBL8760014 | 0.85 | ACE (0.53) | ACEOPRK1 | |
| SCHEMBL10783008 | 0.85 | ACE (0.53) | ACEOPRK1 | |
| SCHEMBL8760024 | 0.85 | ACE (0.53) | ACEOPRK1 | |
| SCHEMBL2182440 | 0.83 | DPP4 (0.52) | DPP4DPP7DPP8DPP9ACE | |
| SCHEMBL31127563 | 0.80 | OPRK1 (0.53) | ACENTSR2NTSR1CAPN1OPRK1 | |
| SCHEMBL29530904 | 0.80 | XIAP (0.48) | ACENTSR2NTSR1GRB2CAPN1 | |
| SCHEMBL3055324 | 0.80 | DPP4 (0.44) | DPP4DPP7DPP8DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289565-B1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | BRACCO SUISSE SA (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO SUISSE S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-8263739-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| EP-2286843-A2 | Compounds for targeting endothelial cells | Bracco Suisse SA (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |
| EP-2279757-A2 | Compounds for targeting endothelial cells | Bracco Suisse SA (CH) | 2011-02-02 | — | — | EP | disclosed |
| US-7820621-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2010-10-26 | — | — | US | disclosed |
| US-20060263303-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO INTERNATIONAL BV (NL) | 2006-11-23 | — | — | US | disclosed |
| US-20060258566-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO INTERNATIONAL BV (NL) | 2006-11-16 | — | — | US | disclosed |
| US-7109167-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20060153775-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2006-07-13 | — | — | US | disclosed |
| EP-1289565-A2 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | Bracco Research USA (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO SUISSE SA (CH) | 2002-10-10 | — | — | US | disclosed |
| WO-2001091805-A2 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | BRACCO RESEARCH USA (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060153775-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | VCAM1, FLT1, EDNRA | DPP4 2131/4885DPP7 2172/4885DPP8 2242/4885 |
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | DPP4 2131/4885DPP7 2172/4885DPP8 2242/4885 |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | VCAM1, FLT1, EDNRA | DPP4 2131/4885DPP7 2172/4885DPP8 2242/4885 |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | VCAM1, FLT1, EDNRA | DPP4 2131/4885DPP7 2172/4885DPP8 2242/4885 |
| US-20060263303-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | DPP4 2131/4885DPP7 2172/4885DPP8 2242/4885 |
| US-20060258566-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | DPP4 2131/4885DPP7 2172/4885DPP8 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.